HUPERZINE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 石杉碱甲是一种从中草药石杉中提取的天然胆碱酯酶抑制剂。有证据表明，在症状疗效方面，石杉碱甲可与目前使用的胆碱酯酶抑制剂相媲美。此外，石杉碱甲具有抗氧化和神经保护特性，这表明它可能对阿尔茨海默病(AD)的疾病修正治疗有用。该药物目前在中国以S营养制剂的形式出售，一些美国临床医生正在使用该药物治疗AD。然而，除中国外，尚无评估其毒性和疗效的临床对照试验。 研究的主要目的是确定石杉碱甲200微克的治疗可以改善阿尔茨海默病患者的认知功能。 次要目标是： 为了确定石杉碱甲400微克BID治疗是否能改善AD患者的认知功能。 目的：确定石杉碱甲治疗对阿尔茨海默病患者的整体临床状态、日常生活能力和行为的影响。 评价石杉碱甲治疗AD的耐受性，剂量分别为200ug/d和400ug/d。 目的：探讨石杉碱甲治疗AD患者血胆碱酯酶活性与认知功能的关系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is eveidence that huperine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). the drug is currently available as s nutriceutical in this country, and is being used by some U.S. clinicans to treat AD. However, ther have been no controlled clinical trails outside China assessing its toxicity and efficacy. The primary aim is to determine treatment with huperzine A 200ug bid improves cognitive function in patients with AD. Secondary Aims are: To determine whether treatment with huperzine A 400ug bid improves cognitive function in patients with AD. To determine the effect of huperzine A treatment on global clinical status, activities of daily living, and behavior in AD. To evaluate the tolerability of huperzine A treatment at dosages of 200ug bid and 400ug bid in AD. To determine the relationship between blood cholinesterase activity and cognitive function in AD patients treated with huperzine A.